Skip To Main Content
Laura Michael on Muck Rack

Laura Michael

As seen in: Maldon & Burnham Standard, MSN UK, Nature, JAMA (The Journal of the American Medical Association), JAMA: Journal of the American Medical Association, Yale Daily News, Echo (Essex), JACC (Journal of the American College of Cardiology), The Daily Gazette (Colchester, UK), The Armenian Weekly, Braintree and Witham Times and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Laura

Contact Laura, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Unraveling the physiological impact of ANGPTL8 loss-of-function variants in humans

|
By Yan Chen, Kylia Williams, Eugene Y. Zhen, Hongxia Li, Thomas Beyer, Muhammad Jahanzaib, Muhammad Mian, Riffat Sultana, Anjum Jalal, Shahid Abbas, Saima Mohsin Verified, Shahid Mukhtar, Adil Mahmood, Timothy Ryan, Laura Michael, Giacomo Ruotolo, Danish Saleheen, Yi Wen, Robert Konrad, Pallav Bhatnagar, Arkan Abadi, Maryalice Hartley, Danisha DeBowles, Yue-Wei Qian, Asif Rahseed, Ambreen Muddassir
| Nature Verified
Abstract Angiopoietin-like 8 (ANGPTL8) is a calorically responsive regulator of lipoprotein lipase (LPL). It does this by forming complexes with ANGPTL3 or ANGPTL4 that either inhibit LPL in oxidative tissues or preserve LPL activity in adipose tissue, respectively. Human heterozygous (reference allele/alternate allele, R/A) carriers of rs145464906/p.Q121X and rs760351239/p.Q131X ANGPTL8 protein truncating variants (PTVs) have favorable lipid profiles and decreased cardiovascular risk.
Open in Who Shared Issue with article?

Petition launched calling for A120 to be dualled between Marks Tey and Braintree

|
By Laura Michael
| MSN UK Verified
; ; ; ; Continue reading More for You ; ; ; Continue reading More for You
Open in Who Shared Issue with article?

Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a)

|
By Steven Nissen, Kathy E. Wolski, Laura Michael
| JAMA: Journal of the American Medical Association Verified
Key Points Question What is the safety and tolerability of lepodisiran, which is a short interfering RNA directed at hepatic production of apolipoprotein(a), and the effect on lipoprotein(a) serum concentrations at doses from 4 mg to 608 mg through 336 days (48 weeks) of follow-up? Findings The trial enrolled 48 participants without cardiovascular disease and with lipoprotein(a) concentrations of 75 nmol/L or greater (or ≥30 mg/dL). A single serious adverse event occurred.
Open in Who Shared Issue with article?
See all 11 licensed articles (48 Total)